



News from the Company 2018 - 08 - 17

RhoVac AB participates in two international conferences and several investment events in Sweden

RhoVac AB ("RhoVac") announces today that it will attend Nordic Life Science Days, Stockholm in September and at BIO-Europe, Copenhagen in November. The company will also attend three investment events in the fall.

RhoVac will attend Nordic Life Science Days, Stockholm Waterfront, Stockholm between 10 and 12 September, and at BIO - Europe in Copenhagen, Denmark between 5 and 7 November. At BIO-Europe, over 2 200 different companies, academic institutions and other related organizations from more than 60 other countries attend.

RhoVac's CEO Anders Ljungqvist will present the company at the Sedermerdagen in Göteborg (11th October, Elite Hotel) and be interviewed in Stockholm (7th November, Waterfront Congress Center). Registration for these events via Sedermera's website, <https://www.sedermera.se/>

The company will also present at Aktiepararnas Aktieträff in Kristianstad on 30th August. Registration can be done via: <https://www.aktiespararna.se/aktiviteter/aktietraff-23>

For more information, please contact:

Anders Ljungqvist – VD, RhoVac AB

Phone: +45 4083 2365

E-mail: alj@rhovac.com

About RhoVac AB

RhoVac AB conducts research and development of immunotherapeutic drugs. The company's main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. RhoVac's top-line results from the clinical phase I / II study has been published 1 August 2018. RhoVac has its head office at Medicon Village in Lund, Sweden. The research has been conducted since 2007 primarily at the University Hospital in Herlev, Denmark, by a world-class research team in its niche. RhoVac is listed on AktieTorget, Sweden, a Multilateral Trading Facility (MTF), since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com.